Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Minjuvi Or Monjuvi Market Size And Revenue Forecast Through 2030
The expansion observed during the historic period has been driven by a higher prevalence of diffuse large B-cell lymphoma, a growing utilization of biologic cancer treatments, the broadening of oncology care facilities, increased physician experience with monoclonal antibodies, and the presence of well-equipped infusion centers.
The expansion observed during the forecast period is driven by a rising need for individualized cancer therapies, higher funding directed toward biologics research in oncology, a growing number of approved combination treatment protocols, an increased emphasis on outpatient cancer care, and a broader uptake of targeted immunotherapies. Key developments influencing this period include the growing implementation of monoclonal antibody therapies specifically designed for target cells, the more frequent application of combined treatment strategies for lymphoma, a stronger focus on precision-based oncology methods, the widening scope of CD19-targeted treatment uses, and a heightened priority on achieving better patient results.
Download A Free Sample Report For Comprehensive Market Insights:
Minjuvi Or Monjuvi Market Demand Drivers Creating New Revenue Opportunities
The rising incidence of cancer is anticipated to drive expansion in the minjuvi or monjuvi market going forward. Cancer encompasses a collection of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells within the body. This growing prevalence is linked to factors like aging, lifestyle choices such as smoking and poor nutrition, environmental exposures, genetic predispositions, and enhanced diagnostic capabilities. Minjuvi (Monjuvi), when used alongside lenalidomide, is indicated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), broadening therapeutic options by effectively targeting malignant cells. As an example, a report released in August 2024 by the Australian Institute of Health and Welfare—a national agency focused on health and welfare statistics in Australia—projects that by 2034, around 209,000 new cancer diagnoses will occur in Australia, marking a notable rise from the estimated 169,000 cases expected in 2024. Furthermore, cancer is predicted to be responsible for roughly 3 out of every 10 deaths in the country during 2024. Consequently, the increasing prevalence of cancer is fostering growth in the minjuvi or monjuvi market.
Minjuvi Or Monjuvi Market Segment Breakdown: Which Categories Generate The Most Revenue?
The minjuvi or monjuvi market covered in this report is segmented –
1) By Indication: Relapsed Or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Other B-Cell Malignancies
2) By Formulation: Intravenous Infusion, Pre-Filled Syringes
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Geriatric Patients
Minjuvi Or Monjuvi Market Trends Driving Strategic Industry Expansion
A notable development in the Minjuvi or Monjuvi market involves the advancement of innovative therapeutic approaches, such as combination regimens, designed to enhance treatment effectiveness and patient outcomes for B-cell malignancies, particularly relapsed or refractory DLBCL. Through combination therapy, two or more treatments—like drugs or other modalities—are used together to manage a disease, aiming to boost overall efficacy by engaging multiple pathways or mechanisms involved in the condition. As an illustration, in February 2024, Knight Therapeutics Inc., a Canada-headquartered pharmaceutical company, rolled out Minjuvi (tafasitamab) via its Brazilian affiliate, United Medical Ltda., pairing it with lenalidomide as an immunotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCl) patients who are not candidates for autologous stem cell transplantation. This combination has achieved a significant objective response rate and, according to NCCN guidelines, is regarded as a preferred second-line treatment.
Minjuvi Or Monjuvi Market Key Players And Strategic Industry Positioning
Major companies operating in the minjuvi or monjuvi market are Incyte Corporation
Access The Complete Minjuvi Or Monjuvi Market Report:
Minjuvi Or Monjuvi Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the minjuvi or monjuvi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minjuvi or monjuvi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model